EN | UA
EN | UA

Help Support

Back

Is biologic use for inflammatory skin diseases safe during COVID-19 pandemic?

Is biologic use for inflammatory skin diseases safe during COVID-19 pandemic? Is biologic use for inflammatory skin diseases safe during COVID-19 pandemic?
Is biologic use for inflammatory skin diseases safe during COVID-19 pandemic? Is biologic use for inflammatory skin diseases safe during COVID-19 pandemic?

What's new?

The use of biologic drugs for the management of inflammatory skin diseases during COVID-19 seems to be safe.

Biologic therapy for inflammatory skin disorders such as psoriasis, atopic dermatitis, palmoplantar pustulosi, and hidradenitis suppurativa appears to be safe for use during SARS-CoV-2 pandemic, as per the findings of a single-center survey published in The Journal of Dermatology. Investigators undertook this epidemiological study for analyzing the trend of biologics use for inflammatory skin diseases during the SARS-CoV-2 era.

The study recruited 227 people having psoriasis, 6 people having palmoplantar pustulosis, 69 people having atopic dermatitis, and 5 people having hidradenitis suppurativa. In 25 people having psoriasis (11.0%), bioswitch was carried out. Biologics were discontinued in 14 people having psoriasis (6.2%), 10 people having atopic dermatitis (14.5%), and 4 people having hidradenitis suppurativa (80.0%). In people having  palmoplantar pustulosis, biologics were not discontinued.

The introduction of biologics was noted in 27 people having psoriasis (11.9%), 4 people having palmoplantar pustulosis (66.7%), 33 people having atopic dermatitis (47.8%), and 2 people having  hidradenitis suppurativa (40.0%). The utilization of telephone consultations was noted in 4 people having psoriasis and 2 people having atopic dermatitis.

Notably, 1 male patient who was given adalimumab to treat psoriatic arthritis, suffered from coronavirus infection and was reported to recover after a mild course. More evidence-based data on a larger number of patients is required to authenticate the benefits and risks of biologic use during the COVID-19 outbreak, concluded the study authors.

Source:

The Journal of Dermatology

Article:

Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic

Authors:

Soichiro Kado et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: